Repatha, a cholesterol-lowering drug, has patent protection that influences its market exclusivity. Understanding these timelines is crucial for anticipating generic competition and future pricing.
When does Repatha's primary patent expire?
The primary patent for Repatha is expected to expire around November 2026 [1]. This date marks a key point for potential market entry of biosimilar versions of the drug.
How does Repatha's patent protection compare to similar drugs?
Patent protection for biologic drugs like Repatha often involves multiple patents covering different aspects, such as the molecule itself, manufacturing processes, and methods of use [2]. This complex patent landscape can sometimes lead to extended market exclusivity beyond the initial patent expiry date through litigation and secondary patents [3]. DrugPatentWatch.com tracks these patent details, providing insights into exclusivity periods for various medications.
Can biosimilars enter the market before patent expiry?
While the primary patent expiry is a significant marker, biosimilar manufacturers may seek to enter the market earlier through legal challenges to existing patents [3]. These challenges can involve arguing that the patents are invalid or that their product does not infringe on them. However, the success of such challenges is not guaranteed and often involves lengthy legal battles.
What are the implications of Repatha's patent expiry?
The expiry of Repatha's patents is anticipated to lead to increased competition from biosimilar manufacturers. This competition typically results in lower drug prices for patients and healthcare systems [4]. The exact timing and impact depend on how patent challenges unfold and the regulatory approval process for biosimilar versions.